Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents

Journal Article

© 2020 - IOS Press and the authors. All rights reserved. BACKGROUND: Nearly 70% of all new cases of bladder cancer are non-muscle invasive disease, the treatment for which includes transurethral resection followed by intravesical therapy. Unfortunately, recurrence rates approach 50% in part due to poor intravesical drug delivery. Hyperthermia is frequently used as an adjunct to intravesical chemotherapy to improve drug delivery and response to treatment. OBJECTIVE: To assess the solubility profile of intravesical chemotherapies under varying conditions of pH and temperature. METHODS: Using microplate laser nephelometry we measured the solubility of three intravesical chemotherapy agents (mitomycin C, gemcitabine, and cisplatin) at varying physical conditions. Drugs were assessed at room temperature (23°C), body temperature (37°C), and 43°C, the temperature used for hyperthermic intravesical treatments. To account for variations in urine pH, solubility was also investigated at pH 4.00, 6.00, and 8.00. RESULTS: Heat incrementally increased the solubility of all three drugs studied. Conversely, pH largely did not impact solubility aside for gemcitabine which showed slightly reduced solubility at pH 8.00 versus 6.00 or 4.00. Mitomycin C at the commonly used 2.0mg/mL was insoluble at room temperature, but soluble at both 37 and 43°C. CONCLUSIONS: Hyperthermia as an adjunct to intravesical treatment would improve drug solubility, and likely drug delivery as some current regimens are insoluble without heat. Improvements in solubility also allow for testing of alternative administration regimens to improve drug delivery or tolerability. Further studies are needed to confirm that improvements in solubility result in increased drug delivery.

Full Text

Duke Authors

Cited Authors

  • Grimberg, DC; Shah, A; Tan, WP; Etienne, W; Spasojevic, I; Inman, BA

Published Date

  • January 1, 2020

Published In

Volume / Issue

  • 6 / 4

Start / End Page

  • 461 - 470

Electronic International Standard Serial Number (EISSN)

  • 2352-3735

International Standard Serial Number (ISSN)

  • 2352-3727

Digital Object Identifier (DOI)

  • 10.3233/BLC-200350

Citation Source

  • Scopus